Also trades as: 0A8E.L (LSE) · $vol 0M
XERS NASDAQ
Xeris Biopharma Holdings, Inc.
1W: -6.1%
1M: +6.3%
3M: +24.7%
YTD: +42.2%
1Y: +13.5%
3Y: +500.6%
5Y: +435.9%
$10.45
+0.24 (+2.35%)
Weekly Expected Move ±9.7%
$8
$9
$10
$11
$12
Credit Risk of going bust: higher than 52% of companies Debt: 13.2% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the middle of the pack, about 1 in 580 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.19 (down 98%), Xeris Biopharma Holdings, Inc. would be worth roughly what it owes.
Total debt $289.4M against a stock market value of $1.91B.
Distance to default 4.90 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $158.2M (short-term plus half of long-term), stock volatility 54.6%; Altman Z'' -4.14. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.19 (down 98%), Xeris Biopharma Holdings, Inc. would be worth roughly what it owes.
Total debt $289.4M against a stock market value of $1.91B.
Distance to default 4.90 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $158.2M (short-term plus half of long-term), stock volatility 54.6%; Altman Z'' -4.14. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
1 relationships1
As Filer
counterparties named
0
As Counterparty
mentioned by others
1
Rel. Types
2022-03-10
Earliest Filing
2022-03-10
Latest Filing
partner: 1
Counterparties (Filed by XERS)
1 relationshipsCompanies named in XERS's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| CME Group Benchmark Administration Limited | — | partner | Provider of the CME Group Benchmark Administration Limited Term SOFR rate | 2022-03-10 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-10-14 | Other Events | View | |
| 2026-09-09 | Regulation FD; Exhibits | View | |
| 2026-08-06 | Earnings Release; Exhibits | View | |
| 2026-07-17 | Unregistered Equity Sales; Other Events | View | |
| 2026-06-30 | Officer/Director Change; Regulation FD; Exhibits | View | |
| 2026-06-11 | Unregistered Equity Sales; Other Events; Exhibits | View | |
| 2026-06-05 | Shareholder Vote | View | |
| 2026-05-07 | Earnings Release | View | |
| 2026-04-21 | Officer/Director Change | View | |
| 2026-03-02 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2026-02-27 | Regulation FD Disclosure; Financial Statements and Exhibits | View | |
| 2026-01-08 | Results of Operations and Financial Condition | View | |
| 2025-12-01 | Regulation FD Disclosure; Financial Statements and Exhibits | View | |
| 2025-11-06 | Results of Operations and Financial Condition | View | |
| 2025-08-07 | Results of Operations and Financial Condition | View | |
| 2025-06-04 | Submission of Matters to a Vote of Security Holders | View | |
| 2025-06-03 | Regulation FD Disclosure; Financial Statements and Exhibits | View | |
| 2025-05-08 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-03-28 | Departure/Election of Directors; Appointment of Officers; Regulation FD Disclosure; Financial Statem | View | |
| 2025-03-06 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR